Xilio Therapeutics announces first patient dosed in Phase 1/2 trial of XTX501 for metastatic NSCLC
XLO•Xilio Therapeutics said the first patient has been dosed in its Phase 1/2 trial of XTX501 in metastatic NSCLC patients previously treated with anti-PD(L)-1; it plans to report initial Phase 1 data in Q4 2027.
1. Trial begins
Xilio Therapeutics said the first patient has been dosed in its Phase 1/2 clinical trial evaluating XTX501 in metastatic NSCLC patients previously treated with anti-PD(L)-1. The company plans to report initial Phase 1 data in Q4 2027.
